TURKU, Finland and BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing ...
Shares in Finnish biotech Faron Pharma are in free fall this morning after a late-stage trial of its lead drug Traumakine for acute respiratory distress syndrome (ARDS) comprehensively failed. The ...
TURKU, FI / ACCESS Newswire / February 9, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Shareholders of Faron Pharmaceuticals Ltd (business ID: 2068285-4, the "Company") are notified of the ...
Hello, everyone. My name is Juho Jalkanen. I'm the CEO of Faron Pharmaceuticals. Welcome to a very important business update. On to the next slide and to the next. A lot has been going on during the ...
Faron Pharmaceuticals may be allowing itself a moment to feel clever. The Finnish biotech posted data on its tumor-associated macrophage candidate bexmarilimab, linking its antibody to one unconfirmed ...
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
In a year already marked by critical scientific milestones, Faron Pharmaceuticals is set to take center stage once again. The clinical-stage biopharmaceutical company has announced that detailed Phase ...
Median overall survival (mOS) with bexmarilimab and azacitidine in relapsed/refractory (r/r) HR-MDS patients reached 14.5 months (increased from 13.4 months observed earlier), a significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results